Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Euro advances against Canadian Dollar despite higher oil prices

Euro advances against Canadian Dollar despite higher oil prices

FXStreetFXStreet2026/06/08 09:30
By:FXStreet

EUR/CAD inches higher after registering over 0.5% losses in the previous day, trading around 1.6070 during the European hours on Monday. The currency cross gains some ground as the commodity-linked Canadian Dollar (CAD) struggles despite higher oil prices.

WTI price rose due to renewed Middle East tensions after Israel and Iran exchanged strikes. The Guardian reported that air raid sirens sounded in Tel Aviv, following the attack from Yemen. The retaliatory attacks from Yemen, whose military force, the Houthis, is backed by Iran, reflect that conflicts in the Middle East have started again.

Earlier, the BBC reported that the Israel Defense Forces (IDF) reportedly struck military targets in Iran following an Iranian missile salvo aimed at northern Israel. This escalation occurred despite US President Donald Trump's criticism of previous Israeli strikes in Beirut and his active push for a diplomatic resolution between Prime Minister Netanyahu and Tehran.

The downside of the Canadian Dollar (CAD) could be restrained due to stronger-than-expected domestic employment data. In May, Canada’s economy added 88,000 jobs, significantly exceeding economic forecasts. This robust labor market performance has reinforced expectations that the Bank of Canada (BoC) may keep interest rates elevated for a longer period than previously anticipated.

On the data front, the Eurozone’s Sentix Investor Confidence data, a key indicator of Investor morale, improves to -13.4 in June from -16.4 in May. Germany’s Factory Orders dropped by 3.8% in April after rising by a revised 4.5% in March. Data missed the estimated 1.2% decrease. On an annual basis, orders increased by 1.6% year-over-year (YoY) in April, as against the previous rise of 4.5% (revised from 5.0%).

Commerzbank’s Rainer Guntermann says a 25-basis-point hike by the European Central Bank (ECB) on Thursday is almost certain and fully priced, marking the first increase since September 2023. He expects no back-to-back move in July, viewing that as premature, but looks for another hike in September. Lower Oil prices should then ease inflation, preventing restrictive policy and opening scope for rate cuts in 2027.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23

Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

智通财经•2026/11/06 12:37
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market